Biotech Values

[DewDiligence]

Bullish things for MNTA that could happen at almost any time:

• FDA tentative approval of MNTA’s Copaxone ANDA (i.e. FDA approval with effective date at expiration of Teva’s Orange Book patents in 2014).

• A partnership deal for M402.

• Disclosures re first three compounds in FoB program with BAX. (I’ve speculated that the compounds are Humira, Orencia, and Erbitux.)

• Monetization of MNTA’s Lovenox royalty stream.

• A buyout offer from BAX, NVS, or someone else.

None of these individual items (except perhaps the first one) is especially likely to happen soon; however, the aggregate probability that at least one of these events happens fairly soon is quite large, IMO.